Cinnamon in the Treatment of Type II Diabetes
|
|
- Brice Rodgers
- 5 years ago
- Views:
Transcription
1 Journal of Interdisciplinary Graduate Research Volume 2 Journal of Interdisciplinary Graduate Research Article Cinnamon in the Treatment of Type II Diabetes Pauline J. Maddox Southern Adventist University, paulinemaddox@msn.com Follow this and additional works at: Recommended Citation Maddox, Pauline J. (2016) "Cinnamon in the Treatment of Type II Diabetes," Journal of Interdisciplinary Graduate Research: Vol. 2, Article 1. Available at: This Article is brought to you for free and open access by KnowledgeExchange@Southern. It has been accepted for inclusion in Journal of Interdisciplinary Graduate Research by an authorized editor of KnowledgeExchange@Southern. For more information, please contact jspears@southern.edu.
2 Cinnamon in the Treatment of Type II Diabetes Cover Page Footnote The purpose of this review of literature was to evaluate the effects of cinnamon on hemoglobin A1C (HbA1c) and fasting blood glucose/fasting plasma glucose (FBG/FPG) in various populations that have type II diabetes, prediabetes, metabolic syndrome, and are overweight or obese. A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL) database using the keywords cinnamon, type II diabetes, diabetes, HbA1c, and FBS. References used in previous meta-analyses were also searched and reviewed for inclusion. Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or FBS/FPG. A total of 15 trials were incorporated in this literature review, 10 studied cinnamon s effect on HbA1c levels and 13 studied cinnamon s effect on the FBG. Six trials showed significant reductions in the HbA1c levels and 10 trials showed significant reductions in the FBG. Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c and FBG levels in type II diabetes. To reduce FBG and HbA1c levels, cinnamon can be dosed at 1 g to 6 g daily with meals (i.e. one to four 500 mg tablets BID or TID with meals). This article is available in Journal of Interdisciplinary Graduate Research:
3 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 1 Cinnamon in the Treatment of Type II Diabetes Pauline Maddox April 6, 2016 Cinnamon in the Treatment of Type II Diabetes A Paper Presented to Meet Partial Requirements For NRSG-594-A Capstone Southern Adventist University School of Nursing Published by KnowledgeExchange@Southern,
4 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 2 Abstract The purpose of this review of literature was to evaluate the effects of cinnamon on hemoglobin A1C (HbA1c) and fasting blood glucose/fasting plasma glucose (FBG/FPG) in various populations that have type II diabetes, prediabetes, metabolic syndrome, and are overweight or obese. A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL) database using the keywords cinnamon, type II diabetes, diabetes, HbA1c, and FBS. References used in previous meta-analyses were also searched and reviewed for inclusion. Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or FBS/FPG. A total of 15 trials were incorporated in this literature review, 10 studied cinnamon s effect on HbA1c levels and 13 studied cinnamon s effect on the FBG. Six trials showed significant reductions in the HbA1c levels and 10 trials showed significant reductions in the FBG. Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c and FBG levels in type II diabetes. To reduce FBG and HbA1c levels, cinnamon can be dosed at 1 g to 6 g daily with meals (i.e. one to four 500 mg tablets BID or TID with meals). 2
5 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 3 Cinnamon in the Treatment of Type II Diabetes Diabetes affects people of all races, ethnicities, ages, and genders and can significantly alter quality of life, especially when not well controlled. Conditions such as metabolic syndrome and prediabetes often result in diabetes within a few years. Controlling these syndromes and diabetes becomes a dilemma when it is coupled with the cost of medications, for those with health insurance as well as for those without. The United States Census Bureau stated that 42 million Americans did not have health insurance in 2013 (Smith & Medalia, 2014). These individuals have the full burden of paying for their own health care costs. The average cost of diabetic medications, supplies, and provider appointments, etc., is estimated at $13,700 per year (American Diabetes Association, 2015). Individuals suffering from the aforementioned prediabetic conditions and diabetes are often started on medications such as Metformin and are seen quarterly by their providers, and therefore have increasing medical expenses. Piette, Heisler, and Wagner (2004) stated, Out-of-pocket medication costs pose a significant burden to many adults with diabetes (p. 384). As a result, 20% of individuals with diabetes forgo taking their medications, as prescribed, in an effort to reduce their out-ofpocket expenses (Piette, Heisler, & Wagner, 2004). If diabetes is not well controlled, the long term effects can be costly, as well as deadly, as diabetes can lead to comorbidities such as neuropathy, retinopathy, nephropathy, hypertension, dermatological problems, and amputations, etc. It is imperative that prediabetic states and diabetes be well controlled to improve the quality of life within these disease processes and to reduce the long term cost of comorbidities associated with these illnesses. New cost effective alternatives, such as cinnamon supplementation, need to be identified to help reduce long term side effects and the out-of-pocket expenses for prediabetic states and diabetes. Published by KnowledgeExchange@Southern,
6 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 4 Cinnamon has been widely used for decades as a dietary supplement for diabetes, especially in countries like China. Due to both the costs and side effects associated with traditional pharmaceuticals in the United States, there has been a growing awareness of natural and/or alternative supplements. Their use is increasing even though the Food and Drug Administration (FDA) does not regulate or manage the manufacturing of herbal remedies. Shane-McWhorter (2013) found that 67% of diabetics used herbal supplements such as cinnamon to lower their blood glucose levels, which may imply a desire to self-treat their diabetes. Lu et al. (2012) found that cinnamon supplementation is able to significantly improve blood glucose control in Chinese patients with type II diabetes (p. 1). Cinnamon has been shown to reduce insulin resistance, reduce blood glucose and lipid levels, reduce inflammation, and increase antioxidant activity (Qin, Panicker, & Anderson, 2010). Despite these benefits and wide spread use of cinnamon and other natural supplements, most traditional providers in the United States do not prescribe or recommend cinnamon or other natural supplements. This may be due to the lack of regulation and approval by the FDA and the lack of evidence of efficacy, or may be due to their own belief or perceptions about cinnamon and other natural supplements. Whatever the reason, there may not be enough information to influence providers to act. Increased studies that show support for cinnamon use in the treatment of type II diabetes, metabolic syndrome, and prediabetes may be the cue to action that is needed. There are only a handful of studies that have been done on the effects of cinnamon in treating type II diabetes and not all show positive results. A few studies have been done on the effects of cinnamon on other disease processes as well as on healthy individuals. Wang et al. (2007) studied the effects of cinnamon on women with Polycystic Ovary Syndrome (PCOS). Results showed significant reductions in insulin resistance in the cinnamon group but not in the 4
7 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 5 placebo group. Solomon and Blannin (2007 & 2009) examined the effects of cinnamon on healthy individuals using an oral glucose tolerance test (OGTT). Their trials showed that cinnamon 5 g and 3 g, respectively, can reduce glucose responses to OGTT and improve insulin sensitivity in healthy individuals. Hlebowicz, Darwiche, Björgell, and Almér (2007) and Hlebowicz et al. (2009) also showed the efficacy of cinnamon in healthy individuals on postprandial blood glucose, gastric emptying, satiety, serum insulin, GLP-1 concentrations, GIP, gherlin, and GER. Prior meta-analyses have focused primarily on the type II diabetic population or have excluded studies that did not report specific biochemical markers like fasting blood sugar (FBS) (Davis & Yokoyama, 2011). There is a need for a more comprehensive review of the effects of cinnamon on multiple biochemical measures as well as multiple disease processes. The purpose of this review of literature was to evaluate the effects of cinnamon on hemoglobin A1C (HbA1c) and fasting blood glucose/fasting plasma glucose (FBG/FPG) in various populations, including those with type II diabetes, prediabetecs, metabolic syndrome, and are overweight or obese. Theoretical Framework The theoretical framework utilized for this research proposal was the Health Belief Model applied mostly from the perspective of the provider. This model theorizes that belief and perceptions influence actions (Glanz, & Rimer, 2005). The researcher has predicted that there is a relationship between cinnamon therapy and reduction of some biochemical measures; however, providers do not currently prescribe or recommend its use. The Health Belief Model describes how modifiable variables and perceived ideas such as severity of consequences, susceptibility, benefits versus barriers, and cues to action can bring about the likelihood of engaging in actions that can promote health (Glanz, & Rimer, 2005). Published by KnowledgeExchange@Southern,
8 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 6 Providers are aware of the susceptibility and severity of type II diabetes. They can be educated about the perceived benefits of cinnamon, i.e., efficacy in lowering HbA1c levels and blood glucose levels, low cost, and no side effects (unless there is an allergy to cinnamon). The perceived barriers to prescribing cinnamon are the lack of FDA regulation of cinnamon, lack of recommendation by the American Diabetic Association (ADA), lack of knowledge of the efficacy of cinnamon in lowering some biochemical measurements, and presumed lack of research to support its use. Cues to action may be evidence-based trials that show benefits and effectiveness of cinnamon in the treatment of type II diabetes and other disease states, while reducing variables such as the dosing amount of cinnamon. With knowledge of such trials, primary care providers may be influenced to act and prescribe this supplement. Providers, therefore, will be promoting health and self-sufficiency in their patients, as their patients will be less dependent on multiple medications and have fewer medication-induced side effects. Materials and Methods A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL) database using the keywords, cinnamon, type II diabetes, diabetes, HbA1c, and FBS. References used in previous meta-analyses were also searched and reviewed for inclusion. Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or FBS/FPG. Studies on type I diabetes were excluded because individuals diagnosed with type I diabetes have a deficiency of insulin rather than insulin resistance, and this literature review is focused on insulin resistance. Another study excluded was done by Wainstein et al. (2011) on individuals diagnosed with type II diabetes because the cinnamon tablets contained cinnamon, zinc gluconate and tri-calcium phosphate. Also not included in this review were studies done on rats. 6
9 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 7 A total of 15 trials were incorporated in this literature review. Thirteen of the trials studied the effects of cinnamon on individuals with type II diabetes, one trial assessed the effects of cinnamon on prediabetic and metabolic syndrome individuals, and one trial studied the efficacy of cinnamon use in overweight or obese individuals. Of these trials, 10 measured HbA1c levels and 13 measured FBG. Other biochemical markers were measured but are not part of this review. Results HbA1c The HbA1c level measures the average blood sugars over a three-month period, and is important in diabetic management because higher HbA1c levels denote greater risk of developing diabetes-related complications. Crawford (2009) studied whether 1 gram of cinnamon cassia taken daily for 90 days would lower HbA1c levels in poorly controlled type II diabetes. Cinnamon 1 g daily was found to have lowered HbA1c levels by 0.83% (p < 0.001). Usual care alone without cinnamon, lowered the HbA1c 0.37% (p < 0.16). Crawford concluded that cinnamon does lower HbA1c for this population. Lu et al. (2012) also studied the effect of cinnamon on HbA1c levels for participants with type II diabetes. Cinnamon extract prepared from the bark of Chinese Cinnamomum aromaticum was used. In this study, they compared a placebo, low dose cinnamon (120 mg), and high dose cinnamon (360 mg). The cinnamon or placebo tablets were taken every morning before breakfast for three months. After three months, they found that for those in the low dose group, HbA1c was reduced an average of 0.67% (8.90 ± 1.24 to 8.23 ± 0.99), (p =.003), and in the high dose group an average of 0.92% (8.92 ± 1.35 to 8.00 ± 1.00), (p = ). In this study, the higher dose was more effective than the lower dose. Published by KnowledgeExchange@Southern,
10 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 8 The effect of cinnamon supplementation was again studied by Sharma, Sharma, Agrawal, Agrawal, and Singhal (2012) in individuals with newly diagnosed type II diabetes. One hundred fifty individuals newly diagnosed with type II diabetes were stabilized with diet and exercise for one month prior to beginning the cinnamon supplementation. The participants were randomized into a 3 g cinnamon group, a 6 g cinnamon group, a placebo group. After three months, the 3 g group s (taking 1 g after each meal) HbA1c went from 8.47 ± 1.02 at baseline to 7.29 ± 0.83 post intervention, p < In the 6 g group (taking 2 g after each meal), the HbA1c went from 8.10 ± 0.84 at baseline to 7.25 ± 0.81 post intervention, p < Both doses had equivalent efficacy. Vafa et al. (2012) treated type II diabetes with Cinnamomum zeylanicum. Participants took two 500 mg tablets of Cinnamomum zeylanicum at each main meal for eight weeks, for a total of 3 grams daily. The researchers concluded that cinnamon significantly decreased HbA1c (p = 0.008), of the treatment group, compared to the placebo group. It is noted that even though the HbA1c levels of these participants were well controlled at baseline (7.35 ± 0.51), the Cinnamomum zeylanicum was still effective in significantly reducing the mean level overall. Al-Yasiry, Kathum, and Al-Ganimi (2014) studied the hypoglycemic effect of cinnamon on 40 male participants with type II diabetes. The participants were given 0.5 g of ground crude cinnamon 15 minutes after each meal for a total of 1.5 g daily for three months. They found that using 1.5 g of ground cinnamon daily decreased the HbA1c which went from pretreatment to posttreatment, (p < 0.01). Cinnamon cassia usage in individuals diagnosed with type II diabetes was studied by Akilen, Tsiami, Devendra, Robinson (2010). Participants were given one 500 mg tablet of cinnamon cassia with breakfast and dinner and two 500 mg tablets with lunch, for a total of 2 g daily. The ingestion of 2 g of cinnamon each day was found to significantly reduce the HbA1c 8
11 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 9 level, 8.22 ± 1.16 to 7.86 ± 1.42, p < A moderate positive correlation was found between the baseline HbA1c level and the significant drop of the HbA1c level suggesting that cinnamon supplementation for individuals with poorly controlled diabetes may play a positive role in managing their disease, r = 0.567, p = Four studies found no significant difference in the HbA1c levels with the use of cinnamon. Vanschoonbeek, Thomassen, Senden, Wodzig, and van Loon (2006) investigated the effects of 1.5 g per day of cinnamon cassia on HbA1c levels of 25 postmenopausal women with well controlled type II diabetes over a six week time frame. No significant changes were found. It must be noted that an appropriate amount of time was not given for a change to be properly noted in the HbA1c level as this trial was done over six weeks instead of three months. Blevins, Leyva, Brown, Wright, Scofield, and Aston (2007) also showed no significant results of cinnamon on HbA1c levels. For three months, cinnamon cassia 1 g was given daily. It was found that this dosage of cinnamon given daily for three months produced no significant change in HbA1c levels (p > 0.05). Mang et al. (2006) studied the effects of 3 g cinnamon daily on 79 individuals diagnosed with type II diabetes over four months. Their study showed no significant decrease in the HbA1c levels posttreatment. Suppapitiporn and Kanpaksi (2006) examined the efficacy of cinnamon cassia 1.5 g daily on reducing the HbA1c levels of 60 individuals with type II diabetes. After 12 weeks of intervention, it was found that the HbA1c levels decreased in both the placebo group and the cinnamon group. There was a greater reduction of the HbA1c level in the cinnamon group, and more patients in the cinnamon group achieved a HbA1c level of < 7% as compared to the placebo group; however, the reductions were not statistically different, p > Published by KnowledgeExchange@Southern,
12 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 10 The participants in the Vanschoonbeek et al., 2006 trial, the Blevins et al., 2007 trial, and the Mang et al., 2006 trial were all individuals with well controlled diabetes with baseline HbA1c levels of 6.86 to 7.4. DeFronzo, Stonehouse, Han, and Wintle (2010) did a meta-analysis of 59 trials with a total of 8,479 patients on the relationship of baseline HbA1c levels and the effectiveness of 10 different classes of hyperglycemic medications and produced a weighted R2 of 0.35 (p < ). These results showed a positive correlation between the baseline HbA1c levels and magnitude of change of the HbA1c level after treatment with glucose-reducing therapies regardless of drug classification. They further stated that, These observations should be considered when assessing clinical efficacy of diabetes therapies derived from clinical trials, particularly when evaluating data from clinical trials of patients with relatively low baseline HbA1c levels, % (DeFronzo, Stonehouse, Han, & Wintle, 2010, p.309, 314). Lower baseline HbA1c levels prior to intervention produce smaller and less significant changes in the HbA1c levels post intervention. FBG/FPG The most common test used to diagnose diabetes is the fasting blood glucose level. This test is more definitive than random blood glucose tests because it measures the blood glucose level after a period of at least eight hours of fasting (no food or liquids except water), eliminating the chance that the results have been influenced by recent food or beverage intake (OneTouch, no date). Khan, Safdar, Ali Khan, Khattak, and Anderson (2003) conducted the first in vivo study on the use of cinnamon in improving FBG levels. Cinnamon cassia was given 1 g daily as one 500 mg tablet taken at lunch and dinner, 3 g daily as two 500 mg tablets taken at breakfast, lunch, and dinner, or 6 g daily as four tablets taken at breakfast, lunch, and dinner. The 10
13 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 11 researchers found that all three doses of cinnamon reduced the mean FBG serum levels (18-29%, p < 0.05) of the participants in the treatment groups after 20, 40, and 60 days. Anderson et al. (2010) studied the effects of cinnamon cassia 250 mg given twice a day to participants with type II diabetes. After two months it was found that the FBS decreased from 8.85 ± 0.32 pretreatment to 8.19 ± 0.29 mmol/l posttreatment, p < Mang et al. (2006) evaluated the usage of cinnamon cassia 1 g daily for individuals diagnosed with type II diabetes. Participants took the cinnamon as prescribed for four months. The cinnamon group was found to have a significant reduction in the FBG between baseline and post intervention levels (9.26 ± 2.26 to 8.15 ± 1.65 mmol/l, p < 0.001). Ziegenfuss, Hofheins, Mendel, Landis, and Anderson (2006) evaluated the effects of Cinnulin PF 500 mg once a day (which is equivalent to 10 g whole cinnamon powder) on the FBG of prediabetic and metabolic syndrome participants. After 12 weeks, the FBG levels decreased 8.4% from ± 12.8 mg/dl to ± 20.1 mg/dl, p < The efficacy of Cinnulin PF was also studied by Roussel, Hininger, Benaraba, Ziegenfuss, and Anderson (2009) in reducing the FBG of individuals who were overweight or obese. Cinnulin PF 250 mg was taken twice a day for 12 weeks. The FBG dropped from 114 ± 2.2 to 102 ± 4.3 mg/dl, p < 0.05, between pre- and posttreatment with Cinnulin PF. Khan, Khan, and Shah (2010) studied the effects of ground cinnamon 1.5 g on the FBG of participants with type II diabetes. For 30 days the participants ingested 0.5 g of cinnamon three times a day with meals. A significant reduction of the FBG was found with the use of cinnamon (216.3 ± 52.7 to ± 44.9 mg/dl, p < 0.05). In a three month trial, Lu et al. (2012) examined the efficacy of cinnamon cassia 120 mg and 360 mg daily in reducing the FBS in 60 Chinese participants who were diagnosed with type II diabetes. Results showed a statistically significant decrease in both Published by KnowledgeExchange@Southern,
14 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 12 groups. Baseline FBG levels decreased from 9 to 7.99 mmol/l in the 120 mg group, and from to 9.59 mmol/l in the 360 mg group, (p = ). The effects of cinnamon in individuals newly diagnosed with type II diabetes was studied by Sharma, Sharma, Agrawal, Agrawal, and Singhal (2012). One hundred and fifty participants were divided into three groups and given a placebo, 3 g cinnamon, or 6 g cinnamon daily spread out over three meals. FBG levels were drastically reduced in both cinnamon groups. Baseline FBG levels decreased 49% in the 3 g cinnamon group from ± to ± 23.03, and 48% in the 6 g cinnamon group from ± to ± 22.85, (p < 0.001). The effectiveness of Cinnamomum zeylanicum in the reduction of FBG was assessed by Vafa et al. (2012). Two 500 mg tablets were given to 37 participants three times daily for eight weeks. Cinnamomum zeylanicum, also known as true cinnamon, significantly reduced the FBG in the cinnamon group ± 9.11 to ± 17.73, (p < 0.05). Al-Yasiry, Kathum, and Al-Ganimi (2014) determined the hypoglycemic effects of cinnamon on 40 poorly controlled male individuals diagnosed with type II diabetes. Participants were given 1.5 g of cinnamon daily for three months. Cinnamon cassia produced a 27.5% decline in the FBG of the participants, ± to ± 17.85, (p < 0.01). In contrast, some trials found no significant reduction in FBG levels after cinnamon supplementation. Vanschoonbeek, Thomassen, Senden, Wodzig, and van Loon (2006) investigated the effects of cinnamon 1.5 g on FBG levels of 25 postmenopausal women with well controlled type II diabetes over six weeks. Although there was some decline of the FBG in the cinnamon group, 8.37 ± 0.59 to 7.91 ± 0.71, it was not statistically significant, (p > 0.05). Suppapitiporn and Kanpaks (2006) evaluated the effects of cinnamon cassia 1.5 g daily, taken over 12 weeks, on individuals with type II diabetes. No statistical significance was found in the 12
15 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 13 FBG. Blevins et al. (2007) explored the effects of 1 g of cinnamon cassia on 57 non-insulin dependent individuals diagnosed with type II diabetes. After a three month intervention phase, no significant change was noted in the FBG. Discussion and Implications for Practice Type II diabetes is a preventable disease. Choosing a healthy lifestyle with well balanced meals and plenty of exercise can mean the difference between a life of health and a life of illness. The global prevalence of diabetes was estimated at nine percent in 2014 in individuals 18 and over. That is over 350 million people worldwide (World Health Organization, no date) (WHO). Diabetes significantly affects quality of life and leads to death when not well controlled. Over three million people die of diabetes and its comorbidities yearly, mainly because of poor health choices. The Centers for Disease Control and Prevention (2014a, 2014b) (CDC) stated that diabetes was the seventh leading cause of death in As stated in the introduction, the American Diabetic Association estimates the cost of diabetes at $13,700 yearly per person, making diabetes costly as well as deadly. Controlling diabetes and its predecessor diseases, prediabetes and metabolic syndrome, is imperative to improving the health of our country and reducing health care expenditures. Finding safe, efficacious, and cost effective alternative treatments for diabetes is a must. Cinnamon is a promising alternative treatment that has been used for decades as a dietary supplement for diabetes, and is much less expensive than some of the traditional pharmaceuticals used to treat diabetes. Some type II diabetic medications costs $200 - $300 a month or more, while cinnamon costs $20 - $30 a month depending on what dosage is taken. Cinnamon was found to be effective in lowering FBG levels in individuals who are diagnosed as prediabetic, overweight, or obese. Cinnamon cassia, Cinnamomum zeylanicum, Published by KnowledgeExchange@Southern,
16 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 14 and Cinnulin PF have been shown to have similar efficacy in these populations; however, Cinnamomum zeylanicum may be more advantageous when diabetes is more controlled (Akilen, Tsiami, Devendra, and Robinson, 2010) with baseline HbA1c levels less than 8. As stated previously, there is a moderate positive correlation between the baseline HbA1c level and the significant drop of the HbA1c level. The participants of the trials that showed no significant drop in the HbA1c levels after cinnamon intervention all had baseline HbA1c levels of The only trial that showed a significant drop in HbA1c levels that were well controlled at baseline (7.35 ± 0.51) was Vafa et al. (2012). This trial used Cinnamomum zeylanicum (true cinnamon). This review of literature recommends cinnamon as an efficacious and cost effective treatment of uncontrolled type II diabetes which may potentially have some cardiovascular benefits. To reduce FBG and HbA1c levels, cinnamon can be dosed at 1 g to 6 g daily with meals (i.e. one to four 500 mg tablets BID or TID with meals). No adverse effects were seen with any of the cinnamon doses. Patients should be watched for cinnamon allergies, although none were reported in any of the studies reviewed. Conclusion Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c levels and FBG levels in individuals diagnosed with type II diabetes. The majority of the trials reviewed in this meta-analysis showed that cinnamon cassia, Cinnamomum zeylanicum (verum), and Cinnulin PF significantly reduced HbA1c and FBS, and is effective in treating type II diabetes. Cinnamomum zeylanicum (verum) was most effective in treating lower baseline levels of HbA1c. The combined trials in this meta-analysis showed that cinnamon decreased the HbA1c levels between 0.44% %, which is as effective as traditional pharmaceuticals used to treat type II diabetes. 14
17 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 15 Further research needs to be done to evaluate if cinnamon is as equally effective in reducing the HbA1c level and FBG level in the individual with stable type II diabetes (HbA1c level 8.0 or FBG 183) versus the individual with unstable type II diabetes (HbA1c 8.0 or FBG 183), as well as the effectiveness of various types of cinnamon such as cinnamon cassia, Cinnamomum zeylanicum, and Cinnulin PF. Published by
18 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 16 References Akilen, R., Tsiami, A., Devendra, D., & Robinson, N. (2010). Glycated haemoglobin and blood pressure lowering effect of cinnamon in multi ethnic Type 2 diabetic patients in the UK: a randomized, placebo controlled, double blind clinical trial. Diabetic Medicine, 27(10), Al-Yasiry, K., Kathum, W., & Al-Ganimi, Y. (2014). Evaluation of Anti-Diabetic Effect of Cinnamon in Patients with Diabetes Mellitus Type Ii in Kerbala City. Journal of Natural Sciences Research, 4(4), American Diabetes Association. (2014). Statistics about diabetes. Retrieved from Anderson, R. A., Zhan, Z., Luo, R., Guo, X., Guo, Q., Zhou, J.,... Stoecker, B. J. (2010). Cinnamon extract lowers glucose, insulin and cholesterol in people with elevated serum glucose. Journal of Traditional and Complementary Medicine, doi: /jtcme American Diabetes Association. (2014). Statistics about diabetes. Retrieved from diabetes.org/diabetes-basics/statistics/?loc=superfooter American Diabetes Association. (2015). The cost of diabetes. Retrieved from diabetes. org/ advocacy/news-events/cost-of- diabetes.html Anderson, R. A., Zhan, Z., Luo, R., Guo, X., Guo, Q., Zhou, J.,... Stoecker, B. J. (2010). Cinnamon extract lowers glucose, insulin and cholesterol in people with elevated serum glucose. Journal of Traditional and Complementary Medicine, doi: /jtcme
19 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 17 Blevins, S. M., Leyva, M. J., Brown, J., Wright, J., Scofield, R. H., & Aston, C. E. (2007). Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes. Diabetes Care, 30(9), doi:dc [pii] Centers for Disease Control and Prevention. (2014a) national diabetes statistics report.retrieved from statisticsreport. Html Centers for Disease Control and Prevention. (2014b). Diabetes latest. Retrieved from Crawford, P. (2009). Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: A randomized, controlled trial. Journal of the American Board of Family Medicine : JABFM, 22(5), doi: /jabfm Davis, P. A., & Yokoyama, W. (2011). Cinnamon intake lowers fasting blood glucose: metaanalysis. Journal of medicinal food, 14(9), DeFronzo, R. A., Stonehouse, A. H., Han, J., & Wintle, M. E. (2010). Relationship of baseline HbA1c and efficacy of current glucose lowering therapies: a meta analysis of randomized clinical trials. Diabetic medicine, 27(3), Hlebowicz, J., Darwiche, G., Björgell, O., & Almér, L. O. (2007). Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. The American journal of clinical nutrition, 85(6), Hlebowicz, J., Hlebowicz, A., Lindstedt, S., Björgell, O., Höglund, P., Holst, J. J.,... & Almér, L. O. (2009). Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like Published by KnowledgeExchange@Southern,
20 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 18 peptide 1, and ghrelin concentrations in healthy subjects. The American journal of clinical nutrition, 89(3), Khan, A., Safdar, M., Ali Khan, M. M., Khattak, K. N., & Anderson, R. A. (2003). Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care, 26(12), Khan, R., Khan, Z., & Shah, S. (2010). Cinnamon may reduce glucose, lipid and cholesterol level in type 2 diabetic individuals. Pakistan J Nutr, 9(5), Lu, T., Sheng, H., Wu, J., Cheng, Y., Zhu, J., & Chen, Y. (2012). Cinnamon extract improves fasting blood glucose and glycosylated hemoglobin level in Chinese patients with type 2 diabetes. Nutrition Research (New York, N.Y.), 32(6), doi: /j.nutres Mang, B., Wolters, M., Schmitt, B., Kelb, K., Lichtinghagen, R., Stichtenoth, D. O., & Hahn, A. (2006). Effects of a cinnamon extract on plasma glucose, HbA1c, and serum lipids in diabetes mellitus type 2. European journal of clinical investigation, 36(5), National Diabetes Education Initiative. (2015). Diabetes management Guidelines. Retrieved from PG.aspx OneTouch. (no date). Fasting blood glucose test. Retrieved from com/ articles/fasting-blood-glucose-test Piette, J. D., Heisler, M., & Wagner, T. H. (2004). Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care, 27(2),
21 Maddox: Cinnamon in the Treatment of Type II Diabetes Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 19 Qin, B., Panickar, K. S., & Anderson, R. A. (2010). Cinnamon: Potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes. Journal of Diabetes Science and Technology, 4(3), Retrieved from edu/ login?url= search. ebscohost.com/login.aspx?direct=true&db=cmedm&an= &site=eds-live Roussel, A. M., Hininger, I., Benaraba, R., Ziegenfuss, T. N., & Anderson, R. A. (2009). Antioxidant effects of a cinnamon extract in people with impaired fasting glucose that are overweight or obese. Journal of the American College of Nutrition, 28(1), Shane-McWhorter, L. (2013). Dietary supplements for diabetes are decidedly popular: help your patients decide. Diabetes Spectrum, 26(4), Sharma, P., Sharma, S., Agrawal, R., P., Agrawal, V., & Singhal, S. (2012). A randomised double blind placebo control trial of cinnamon supplementation on glycemic control and lipid profile in type 2 diabetes mellitus. Australian Journal of Herbal Medicine, 24(1), 4-9. Retrieved from ttps://ezproxy.southern.edu/login?url= /login.aspx?direct=true&db=ccm&an= &site=ehost-live&scope=site Smith, J. C., & Medalia, C. (2014). Health insurance coverage in the United States: 2013 US Department of Commerce, Economics and Statistics Administration, Bureau of the Census. Solomon, T. P. J., & Blannin, A. K. (2007). Effects of short term cinnamon ingestion on in vivo glucose tolerance. Diabetes, Obesity and Metabolism, 9(6), Solomon, T. P., & Blannin, A. K. (2009). Changes in glucose tolerance and insulin sensitivity following 2 weeks of daily cinnamon ingestion in healthy humans. European journal of applied physiology, 105(6), Published by KnowledgeExchange@Southern,
22 Journal of Interdisciplinary Graduate Research, Vol. 2 [2016], Art. 1 Running Head: CINNAMON IN THE TREATMENT OF TYPE II DIABETES 20 Suppapitiporn, S., & Kanpaksi, N. (2006). The effect of cinnamon cassia powder in type 2 diabetes mellitus. Journal of the Medical Association of Thailand= Chotmaihetthangphaet, 89, S Vafa, M., Mohammadi, F., Shidfar, F., Sormaghi, M. S., Heidari, I., Golestan, B., & Amiri, F. (2012). Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. International Journal of Preventive Medicine, 3(8), 531. Vanschoonbeek, K., Thomassen, B. J., Senden, J. M., Wodzig, W. K., & van Loon, L. J. (2006). Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. The Journal of Nutrition, 136(4), doi:136/4/977 [pii] Wang, J. G., Anderson, R. A., Graham, G. M., Chu, M. C., Sauer, M. V., Guarnaccia, M. M., & Lobo, R. A. (2007). The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertility and sterility, 88(1), Wainstein, J., Stern, N., Heller, S., & Boaz, M. (2011). Dietary cinnamon supplementation and changes in systolic blood pressure in subjects with type 2 diabetes. Journal of medicinal food, 14(12), World Health Organization. (no date). Diabetes. Retrieved from /factsheets/fs312/en/ Ziegenfuss, T. N., Hofheins, J. E., Mendel, R. W., Landis, J., & Anderson, R. A. (2006). Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. Journal of the International Society of Sports Nutrition, 3(2),
Cinnamon in the Treatment of Type II Diabetes
Southern Adventist Univeristy KnowledgeExchange@Southern Graduate Research Projects Nursing Winter 5-4-2016 Cinnamon in the Treatment of Type II Diabetes Pauline J. Maddox Southern Adventist University,
More informationInternational Journal of Pharma and Bio Sciences
Research Article Pharmaceutics International Journal of Pharma and Bio Sciences ISSN 0975-6299 EFFECT OF CINNAMON (CINNAMOMUM CASSIA) INTERVENTION ON METABOLIC FEATURES OF ADULT MALE WITH TYPE 2 DIABETES
More informationEffects of Cinnamon Consumption on Glycemic Status, Lipid Profile and Body Composition in Type 2 Diabetic Patients
Effects of Cinnamon Consumption on Glycemic Status, Lipid Profile and Body Composition in Type 2 Diabetic Patients Mohammadreza Vafa 1,2, Farhad Mohammadi 1, Farzad Shidfar 1, Mohammadhossein Salehi Sormaghi
More information*Corresponding author Omer AA. Musa. Article History Received: Accepted: Published: DOI: /sasjm
SAS Journal of Medicine ISSN 2454-5112 SAS J. Med., Volume-3; Issue-10 (Oct, 2017); p-262-267 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific
More informationCeylon cinnamon does not affect postprandial plasma glucose or insulin in subjects with impaired glucose tolerance.
Ceylon cinnamon does not affect postprandial plasma glucose or insulin in subjects with impaired glucose tolerance. Wickenberg, Jennie; Lindstedt Ingemansson, Sandra; Berntorp, Kerstin; Nilsson, Jan; Hlebowicz,
More informationAnalysis of Blood Glucose and Plasma Insulin Levels of Tea and Cinnamon Tea Drink against People with Diabetes Mellitus Type 2
IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 3, Issue 2 (Mar. Apr. 2017), PP 48-52 www.iosrjournals.org Analysis of Blood Glucose and Plasma Insulin Levels of Tea and
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More information1 From the Departments of Medicine (JH, AH, GD, and L-OA) and Radiology
Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in
More informationCINNAMON CINNAMOMUM VERUM
CINNAMON CINNAMOMUM VERUM This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization.
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationPrediabetes 101. What is it and what can I do about it? Intermountainhealthcare.org/diabetes
Prediabetes 101 What is it and what can I do about it? Patient Education Intermountainhealthcare.org/diabetes What do you already know about prediabetes? Fact or Fiction? There are often no symptoms of
More informationPre Diabetes Screening in Primary Care
University of San Diego Digital USD Doctor of Nursing Practice Final Manuscripts Theses and Dissertations Spring 5-21-2016 Pre Diabetes Screening in Primary Care Christine Rieger crieger@sandiego.edu Follow
More informationApproximately one third of the 15.7 million Americans who are estimated to have diabetes
Diabetes is a very serious illness and too many people are neglecting their condition. Approximately one third of the 15.7 million Americans who are estimated to have diabetes are unaware of their condition.
More informationMetabolic Syndrome Case Presentation. Presented by: Keonie Moore (B. Naturopathy SCU NHAA) IMER The Alfred Hospital 5 June 2013
Metabolic Syndrome Case Presentation Presented by: Keonie Moore (B. Naturopathy SCU NHAA) IMER The Alfred Hospital 5 June 2013 Presenting Complaint: August 2011 51 year female presented with osteopenia
More informationRunning head: SELF-CONTROL DIETARY SELECTIONS 1. Self-Control Dietary Selections and Glycemic Control in Adults with Type II Diabetes:
Running head: SELF-CONTROL DIETARY SELECTIONS 1 Self-Control Dietary Selections and Glycemic Control in Adults with Type II Diabetes: Evidence-Based Practice Yufang Gu Texas Woman s University NURS 6023
More informationErectile Dysfunction as a Motivational Tool for Health Behavior Change in Men with Diabetes
Brigham Young University BYU ScholarsArchive All Student Publications 2014-06-24 Erectile Dysfunction as a Motivational Tool for Health Behavior Change in Men with Diabetes Camille W. Allred Donna Freeborn
More informationCassia cinnamon does not change the insulin sensitivity or the liver enzymes in subjects with impaired glucose tolerance
Wickenberg et al. Nutrition Journal 2014, 13:96 RESEARCH Open Access Cassia cinnamon does not change the insulin sensitivity or the liver enzymes in subjects with impaired glucose tolerance Jennie Wickenberg
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationIf DSME* were a pill, would you prescribe it?
If DSME* were a pill, would you prescribe it? *Diabetes Self-Management Education/Training Jan Kincaid Rystrom, RD CDE MEd Manager, Diabetes Education EvergreenHealth Goals Evaluate DSME as part of ADA
More informationObjectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT
Diabetes- The Real Cost of Sugar By Ruth Nekonchuk RD CDE LMNT Objectives To explain diabetes To explain the risks of diabetes To enumerate the cost of diabetes to our country To enumerate the cost of
More informationA Summary Report: 2003
D iabetes in Idaho A Summary Report: 2003 Idaho Department of Health and Welfare Division of Health Bureau of Community and Environmental Health This publication was supported by Grant No. U32/CCU022691-02
More informationDiabetes Prevention in. Massachusetts: Prediabetes and the Diabetes Prevention Program. Diabetes Prevention and Control
Diabetes Prevention in r Massachusetts: Prediabetes and the Diabetes Prevention Program Diabetes Prevention and Control www.mass.gov/dph/diabetes Massachusetts Department of Public Health 29 million with
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationThe Paleolithic Diet. A Review
The Paleolithic Diet A Review by: Philip Rouchotas, MSc, ND Bolton Naturopathic Clinic 64 King St. W, Bolton, Ontario L7E 1C7 info@boltonnaturopathic.ca What is the Paleolithic Diet? Today s modern diet
More informationTreating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background
Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationNational Diabetes Fact Sheet, 2011
National Diabetes Fact Sheet, 2011 FAST FACTS ON DIABETES Diabetes affects 25.8 million people 8.3% of the U.S. population DIAGNOSED 18.8 million people UNDIAGNOSED 7.0 million people All ages, 2010 Citation
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationExpert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report
Expert Committee s Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report (1) Overview material Release Date December 2007 Status Available in
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More information290 Biomed Environ Sci, 2016; 29(4):
290 Biomed Environ Sci, 2016; 29(4): 290-294 Letter to the Editor Prevalence and Predictors of Hypertension in the Labor Force Population in China: Results from a Cross-sectional Survey in Xinjiang Uygur
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More informationShaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact
Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact Task Force for the National Conference on Diabetes: The Task Force is comprised of Taking Control of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe National Diabetes Prevention Program in Washington State March 2012
The National Diabetes Prevention Program in Washington State March 2012 Session Objectives 1. Overview of pre-diabetes. 2. Describe the Diabetes Prevention Program (DPP). 3. Eligibility for the DPP. 4.
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationAmerican Diabetes Association: Standards of Medical Care in Diabetes 2015
American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationIntroduction. Patricia Whitfield 1 Amber Parry Strong 1 Emily Walsh 1 Mark Weatherall 2 Jeremy D. Krebs 1,2
DOI 10.1007/s00394-015-0926-x ORIGINAL CONTRIBUTION The effect of a cinnamon, chromium and magnesium formulated honey on glycaemic control, weight loss and lipid parameters in type 2 diabetes: an open
More informationNational Diabetes Fact Sheet, 2007
National Diabetes Fact Sheet, 2007 General Information What is diabetes? Diabetes is a group of diseases marked by high levels of blood glucose resulting from defects in insulin production, insulin action,
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationDiabetes Prevention (Managing Prediabetes)
IMPORTANCE OF FOCUS Although Prediabetes is not viewed as a clinical entity in its own right, it is a risk factor for diabetes and cardiovascular disease. It is estimated that approximately 1 in 3 U.S.
More informationProvider Bulletin December 2018 Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes
Medi-Cal Managed Care L. A. Care Provider Bulletin December 2018 provider guide to coding the diagnosis and treatment of diabetes Diabetes mellitus is a chronic disorder caused by either an absolute decrease
More informationFructose in diabetes: Friend or Foe. Kim Chong Hwa MD,PhD Sejong general hospital, Division of Endocrinology & Metabolism
Fructose in diabetes: Friend or Foe Kim Chong Hwa MD,PhD Sejong general hospital, Division of Endocrinology & Metabolism Contents What is Fructose? Why is Fructose of Concern? Effects of Fructose on glycemic
More informationGoals of today s talk. How to Stop Prediabetes from Becoming Diabetes. Goals of today s talk. Type 2 diabetes mellitus
Goals of today s talk How to Stop Prediabetes from Becoming Diabetes Zara Frankel, MD Boulder Creek Family Medicine 303-720-6956 Diabetes is a devastating disease Prediabetes and diabetes are on different
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationCoding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes
Medicaid Managed Care December 2018 provider guide to coding the diagnosis and treatment of diabetes Diabetes mellitus is a chronic disorder caused by either an absolute decrease in the amount of insulin
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationClinical Care Performance. Financial Year 2012 to 2018
Clinical Care Performance Financial Year 2012 to 2018 SHP Clinical Care Performance Diabetes Mellitus Hyperlipidemia Hypertension Diabetes Mellitus Find out how our patients are doing for: HbA1C HbA1c
More informationWHAT IS INTEGRATIVE MEDICINE?
WHAT IS INTEGRATIVE MEDICINE? Integrative medicine is an approach to care that puts the patient at the center and addresses the full range of physical, emotional, mental, social, spiritual and environmental
More informationManagement of Gestational Diabetes
Management of Gestational Diabetes A Diabetes risk assessment should be ascertained at the First prenatal visit. Low Risk: Early blood glucose screening is NOT routinely required if most of the following
More informationSTATE OF THE STATE: TYPE II DIABETES
STATE OF THE STATE: TYPE II DIABETES HENRY DRISCOLL, MD, CHIEF of ENDOCRINOLOGY MARSHALL U, CHERTOW DIABETES CENTER, HUNTINGTON VAMC HEATHER VENOY, RD, LD, CDE DIETITIAN, DIABETES EDUCATOR, CHERTOW DIABETES
More informationMacronutrients and Dietary Patterns for Glucose Control
제 20 회대한당뇨병학회춘계학술대회 Macronutrients and Dietary Patterns for Glucose Control 2017.5.13 서울대학교병원임정현 Conflict of interest disclosure None Committee of Scientific Affairs Contents Review of Nutrition Recommendation
More informationChapter 1 - General introduction.
Chapter 1 - General introduction. 9 Chapter 1 - General Introduction This thesis reports on six studies that were conducted to get a better understanding of the influence of emotional factors on self-care
More informationEndocrinology. Self-Monitoring Blood Glucose
Endocrinology Self-Monitoring Blood Glucose The Diabetes, Endocrine & Metabolism Centre offers one-stop accessible care to patients and is staffed by experienced endocrinologists, diabetes nurse educators,
More informationLiving Well with Diabetes
Living Well with Diabetes What is diabetes? Diabetes Overview Diabetes is a disorder of the way the body uses food for growth and energy. Most of the food people eat is broken down into glucose, the form
More information= AUDIO. Managing Diabetes for Improved Cardiovascular Health. An Important Reminder. Mission of OFMQ 8/18/2015. Jimmi Norris MS, RN, CDE
Managing Diabetes for Improved Cardiovascular Health Jimmi Norris MS, RN, CDE An Important Reminder For audio, you must use your phone: Step 1: Call (866) 906 0123. Step 2: Enter code 2071585#. Step 3:
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationAdditive postprandial blood glucose attenuating and satiety-enhancing effect of cinnamon and acetic acid
Available online at www.sciencedirect.com Nutrition Research 29 (2009) 723 727 www.nrjournal.com Additive postprandial blood glucose attenuating and satiety-enhancing effect of cinnamon and acetic acid
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationDisclosure. I have no relevant financial relationships with commercial interests to disclose American Medical Association. All rights reserved.
Disclosure I have no relevant financial relationships with commercial interests to disclose. 2 Objectives Describe the trends in type 2 diabetes and implications for clinical practice Review the evidence
More informationSIOFOR mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SIOFOR 850 850mg film-coated tablets METFORMIN HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationCinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome
556 Asia Pac J Clin Nutr 2018;27(3):556-563 Original Article Cinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome Azam Borzoei MSc 1, Maryam
More informationManage Diabetes with Small Changes
In This Issue: } Manage with Small Changes } The Role of Your Educator } Prediabetes: A Call to Action } Insulin and : Your Questions Answered Manage with Small Changes One man learns simple ways to keep
More informationDiabetes Care Begins With Diabetes Prevention
Diabetes Care Begins With Diabetes Prevention Noah Nesin, M.D., FAAFP June 28, 2018 12-1pm Webinar Logistics for Zoom Audio lines for non-presenters are currently muted Please use the Q & A function for
More informationThe clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes
The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes September, 2017 White paper Life Sciences IHS Markit Introduction Diabetes is one of the most prevalent
More informationBuilding Our Evidence Base
Plant-Based Diets Neal D. Barnard, MD, FACC Adjunct Associate Professor of Medicine George Washington University School of Medicine Physicians Committee for Responsible Medicine Washington, DC Building
More informationDiabetes Mellitus and the Dental Healthcare Professional
Diabetes Mellitus and the Dental Healthcare Professional Jerry A. Brown DMD, CDE University of South Florida Department of Internal Medicine jabrown7@health.usf.edu Learning Objectives Diabetes- The Disease
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationSUPPLEMENTARY DATA. Supplementary Methods
Supplementary Methods Chronic kidney disease stage 4 or 5 Current diabetic foot with ulcer, soft tissue infection or necrosis Unstable angina, myocardial infarction, or cerebrovascular accident over the
More informationAm I at Risk for Type 2 Diabetes?
Am I at Risk for Type Diabetes? Taking Steps to Lower Your Risk of Getting Diabetes On this page: What is type diabetes? Can type diabetes be prevented? What are the signs and symptoms of type diabetes?
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationWhy do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?
What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationEffect of bitter gourd clinical trial in prediabetics: blind, randomised, cross over trial in India
Effect of bitter gourd clinical trial in prediabetics: blind, randomised, cross over trial in India Dr.M. Amirthaveni Subramanian & Dr.S.Premakumari Department of Food Science and Nutrition Avinashilingam
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationPeer Review Report. [long acting insulin analogues glargine and detemir]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [long acting insulin analogues glargine and detemir] (1) Does the application adequately address the issue of the public
More informationSummary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)
EMA/217413/2015 Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin) This is a summary of the risk management plan (RMP) for Synjardy, which details the measures to be taken
More informationSubject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119
Acarbose, diabetes prevention trials 32, 33, 40 42 Accelerator hypothesis accelerators beta cell autoimmunity 140, 141, 147, 150, 151 insulin resistance 140, 142 144, 150 obesity 145 148 diabetes risk
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationTAHFA-South Texas HFMA Fall Symposium. Tuesday, October 17, from 10:45 AM 11:35 AM.
1 TAHFA-South Texas HFMA Fall Symposium Tuesday, October 17, from 10:45 AM 11:35 AM. Dr. Anil T. Mangla, MS., PhD., MPH., FRSPH Director of Public Health and Associate Professor of Biomedical Science 2
More informationPatients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study
International Journal of Advances in Medicine Gadge PV et al. Int J Adv Med. 2018 Apr;5(2):424-428 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181082
More informationAbout the Highmark Foundation
About the Highmark Foundation The Highmark Foundation, created in 2000 as an affiliate of Highmark Inc., is a charitable organization and a private foundation that supports initiatives and programs aimed
More informationMonthly WellPATH Spotlight November 2016: Diabetes
Monthly WellPATH Spotlight November 2016: Diabetes DIABETES RISK FACTORS & SELF CARE TIPS Diabetes is a condition in which the body does not produce enough insulin or does not use the insulin produced
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationTargeted Nutrition Therapy Nutrition Masters Course
Targeted Nutrition Therapy Nutrition Masters Course Nilima Desai, MPH, RD Learning Objectives Review clinical studies on innovative, targeted nutrition therapies for: o Blood glucose management o Dyslipidemia
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS
DIABETES MELLITUS 1. Introduction Diabetes is a global epidemic with 415 million people affected worldwide equivalent to the total population of the USA, Canada and Mexico. In recognition of this, the
More informationDIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:
1 DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address: 2 Learning Outcomes All nurses, regardless of practice setting, are required to work collaboratively with the person
More informationDIABETES EDUCATION FOR HEALTH CARE SERIES
American Association of Diabetes Educators Provider is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. DIABETES EDUCATION
More informationMichigan s Diabetes Crisis: Today and Future Trends. Dr. William Rowley Institute for Alternative Futures
Michigan s Diabetes Crisis: Today and Future Trends Dr. William Rowley Institute for Alternative Futures 1 What s Happening to Our Children? During their lifetimes: 1/2 will become obese 1 in 3 males &
More informationManagement of Pregestational and Gestational Diabetes Mellitus
Background and Prevalence Management of Pregestational and Gestational Diabetes Mellitus Pregestational Diabetes - 8 million women in the US are affected, complicating 1% of all pregnancies. Type II is
More information